From: Omalizumab for chronic urticaria in Latin America
Time (months)
No. of patients
Complete response
Partial response
Non-response
3
9
3 (33.3)
4 (44.4)
2 (22.2)
5
4
3 (75.0)
0 (0.0)
1 (25.0)